Neonatal outcomes and immune reprogramming induced by prenatal opioid and hepatitis C exposure

Published: 1 November 2026| Version 2 | DOI: 10.17632/83bh82m9m2.2
Contributor:
Ilhem Messaoudi

Description

Metadata and supporting data points for flow cytometry, ICCS, and luminex. Data supporting the omics analysis is in the NCBI SRA project number PRJNA1234185. abstract: Prenatal opioid exposure (POE) is an escalating public health concern, yet its impact on neonatal immune development remains poorly defined. This study examined how POE, with or without maternal hepatitis C (HCV) infection, shapes neonatal immunity using umbilical cord blood. Pregnancies included uncomplicated term controls and deliveries in patients with severe opioid use disorder on medication-assisted treatment, with (POE HCV+) or without (POE HCV−) HCV infection. POE was associated with smaller birth size, higher rates of congenital anomalies, and longer intensive care admissions. Immune profiling showed a pro-inflammatory milieu, reduced neuroprotective factors, expanded memory/effector T and B cells, blunted T cell responses, and markedly reduced NK cell frequency and cytotoxicity, especially in POE HCV+ newborns. Monocytes exhibited inflammatory reprogramming with impaired antiviral and tissue repair pathways and disrupted lymphoid–innate immune cell communication. These findings suggest POE-driven immune disequilibrium may underlie adverse early-life outcomes and highlight monitoring and intervention targets.

Files

Institutions

Categories

Opioid, Neonatal Immunology

Licence